Chris T Derk, MD, MS
Chris T Derk, MD, MS
Associate Professor of Clinical Medicine
Department: Medicine
Contact information
Division of Rheumatology
8th Floor Penn Tower
One Convention Blvd
Philadelphia, PA 19104
8th Floor Penn Tower
One Convention Blvd
Philadelphia, PA 19104
Office: 215-615-4306
Fax: 215-662-4500
Fax: 215-662-4500
Email:
chris.derk@uphs.upenn.edu
chris.derk@uphs.upenn.edu
Publications
Education:
AA
Harrisburg Area Community College, 1988.
BS (Pre-Medicine)
Pennsylvania State University, 1990.
MD
Thomas Jefferson University, 1994.
MSc (Pharmacology)
Thomas Jefferson University, 2006.
Permanent linkAA
Harrisburg Area Community College, 1988.
BS (Pre-Medicine)
Pennsylvania State University, 1990.
MD
Thomas Jefferson University, 1994.
MSc (Pharmacology)
Thomas Jefferson University, 2006.
Description of Clinical Expertise
Systemic Sclerosis (Scleroderma) and other fibrotic autoimmune connective tissue disorders ( Eosinophilic Faciitis, Scleromyxedema, Scleredema, Nephrogenic Systemic Fibrosis). Raynaud's phenomenon. Systemic Lupus Erythematosus.Description of Other Expertise
Rheumatology based educational models.Description of Research Expertise
Scleroderma clinical outcomes, therapeutic interventions and disease pathogensis. Systemic Lupus Erythematosus clinical outcomes.Selected Publications
Daniel Schneeberger, Alan Tyndall, Jonathan Kay, Klaus H. Sondergaard, Patricia E. Carreira, Ewa Morgiel, Katrin Deuschle, Chris T. Derk, Malgorzata Widuchowska, Ulrich Walker: Systemic Sclerosis without antinuclear antibodies or Raynaud's phenomenon: a multicentre study in the prospective EULAR Scleroderma trials and research (EUSTAR) database. Rheumatology 52: 560-567, December 2012.Schulz SW, Shenin M, Mehta A, Kebede A, Fluerant M, Derk CT.: Initial presentation of acute transverse myelitis in systemic lupus erythematosus: demographics, diagnosis, management and comparison to idiopathic cases. Rheumatol Int. 32(9): 2623-7, Sep 2012 Notes: doi: 10.1007/s00296-011-2053-1. Epub 2011 Jul 22.
Chris T. Derk: Management of the patient with systemic sclerosis. Journal of Clinical Outcomes Measures (JCOM) 19(8), August 2012.
Ba S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, Domsic R, Fischer A, Frech T, Goldberg A, Hinchcliff M, Hsu V, Hummer L, Schiopu E, Mayes D, Mclaughlin V, Molitor J, Naz N, Furst DE, Maranian P, Sten V, Khanna D.: Baseline characteristics and follow-up in patients with normal haemodynamic versus borderline mean pulmonary arterial pressure in systemi sclerosis: results from the PHAROS registry. Ann Rheum Dis. 71(8): 1335-42, Aug 2012 Notes: Epub 2012 Feb 2.
Jain S, Shahane A, Derk CT.: Interstitial lung disease in systemic sclerosis; pathophysiology, current and new advances in therapy. Inflamm Allergy Drug Targets. 11(4): 266-77, Aug 2012.
Ghaith Noaiseh, Sophia Li, Chris T. Derk: Management of gastrointestinal manifestations in systemic sclerosis ( scleroderma). International Journal of Clinical Rheumatology 7(6), 2012.
Derk CT, Huaman G, Littlejohn J, Otieno F, Jimenez S.: Predictors of early mortality in systemic sclerosis: a case control study comparing early versus late mortality in systemic sclerosis. Rheumatol Int Page: Epub ahead of print, Dec 2011.
Johnson J, Derk CT.: Gastric antral vascula ectasia in systemic sclerosis. Int J Rheumatol Page: Epub ahead of print, Nov 2011.
Wipff J, Coriat R, Masciocchi M, Caramaschi P, Derk CT, Hachulla E, Riccieri V, Mouthon L, Krasowska D, Ananyeva LP, Kahan A, Matucci-Cerinic M, Chaussade S, Allanore Y. : Outcomes of Barrett's oesophagus related to systemic sclerosis: a 3-year EULAR Scleroderma Trials and Research prospective follow-up study. Rheumatology (Oxford) 50(8): 1440-4, Aug 2011 Notes: Epub 2011 Mar 16.
Derk, CT.: Disease-modifying drugs for systemic sclerosis: why have we not found them yet? Expert Rev Clin Immunol. 7(4): 399-401, Jul 2011.